Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 4/20 | 0.40 |
| ▸ | RXRB | P28702 | 4/20 | 0.40 |
| ▸ | RXRG | P48443 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | RGS12 | O14924 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1223549 | 0.86 | CYP4F2 (0.42) | KLKB1CTSBPTGS1SLC22A12SMN1; SMN2 | |
| SCHEMBL17424894 | 0.85 | SMN1; SMN2 (0.45) | KLKB1CTSBPTGS1SLC22A12SMN1; SMN2 | |
| SCHEMBL11158364 | 0.85 | CYP4F2 (0.40) | SLC22A12HPGDHSD17B10EGFRLMNA | |
| SCHEMBL25975940 | 0.84 | CA2 (0.41) | EGFRCA2 | |
| SCHEMBL2332010 | 0.84 | SLC22A12 (0.44) | KLKB1CTSBPTGS1SLC22A12SMN1; SMN2 | |
| SCHEMBL9883930 | 0.82 | ALDH1A1 (0.47) | SLC22A12SMN1; SMN2SRCMAPTHPGD | |
| SCHEMBL31422550 | 0.82 | SRC (0.46) | KLKB1CTSBPTGS1SLC22A12SMN1; SMN2 | |
| SCHEMBL148755 | 0.82 | SHBG (0.48) | MAPTHPGDKDM4EHSD17B10TSHR | |
| SCHEMBL29741490 | 0.82 | SHBG (0.48) | MAPTHPGDKDM4EHSD17B10TSHR | |
| SCHEMBL11967053 | 0.80 | BACE1 (0.40) | MAPTHPGDKDM4EHSD17B10EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10196388-B2 | Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2019-02-05 | — | — | US | disclosed |
| US-20180127409-A1 | AZABICYCLIC CARBAMATES AND THEIR USE AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-10 | — | — | US | disclosed |
| US-9714242-B2 | Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-07-25 | — | — | US | disclosed |
| US-20150065537-A1 | AZABICYCLIC CARBAMATES AND THEIR USE AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-03-05 | — | — | US | disclosed |
| US-8772511-B2 | Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-07-08 | — | — | US | disclosed |
| US-20130060039-A1 | AZABICYCLIC CARBAMATES AND THEIR USE AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | BAYER SCHERING PHARMA AG (DE) | 2013-03-07 | — | — | US | disclosed |
| US-8153799-B2 | Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-04-10 | — | — | US | disclosed |
| US-20120046350-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-02-23 | — | — | US | disclosed |
| US-20100324085-A1 | AZABICYCLIC CARBAMATES AND THEIR USE AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | BAYER SCHERING PHARMA AG (DE) | 2010-12-23 | — | — | US | disclosed |
| US-7795453-B2 | Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-09-14 | — | — | US | disclosed |
| US-6239159-B1 | SUBSTRATES FOR POLYMERASE AND TERMINAL TRANSFERASE ENZYMES. CAPABLE OF BASE-PAIRING WITH A NUCLEOTIDE RESIDUE IN A COMPLEMENTARY CHAIN OR BASE STACKING IN THE APPROPRIATE NUCLEIC ACID CHAIN, ADVANTAGE OVER CONVENTIONAL HAPTEN | AMERSHAM PHARMACIA BIOTECH UK LIMITED (GB) | 2001-05-29 | — | — | US | disclosed |
| EP-0904382-A1 | CHARACTERIZATION AND USE OF AN ISOLATED URIDINE DIPHOSPHO-GLUCURONOSYLTRANSFERASE | ENDORECHERCHE INC. (CA) | 1999-03-31 | — | — | EP | disclosed |
| EP-0885235-A1 | NUCLEOSIDE ANALOGUES | Amersham Pharmacia Biotech UK Limited (GB) | 1998-12-23 | — | — | EP | disclosed |
| WO-1997044466-A1 | CHARACTERIZATION AND USE OF AN ISOLATED URIDINE DIPHOSPHO-GLUCURONOSYLTRANSFERASE | ENDORECHERCHE, INC. (CA) | 1997-11-27 | — | — | WO | disclosed |
| WO-1997028176-A1 | NUCLEOSIDE ANALOGUES | AMERSHAM PHARMACIA BIOTECH UK LIMITED (GB) | 1997-08-07 | — | — | WO | disclosed |
| EP-0097050-B1 | ESTERS OF PHOSPHINYLALKANOYL SUBSTITUTED PROLINES | E.R. Squibb & Sons, Inc. (US) | 1986-09-10 | — | — | EP | disclosed |
| US-4494604-A | NEUTRALIZING WITH POTASSIUM HYDROXIDE; WATERFLOODING | PHILLIPS PETROLEUM COMPANY (US) | 1985-01-22 | — | — | US | disclosed |
| US-4468519-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1984-08-28 | — | — | US | disclosed |
| EP-0097050-A1 | Esters of phosphinylalkanoyl substituted prolines | E.R. Squibb & Sons, Inc. (US) | 1983-12-28 | — | — | EP | disclosed |
| US-4232950-A | ANTHRAQUINONE DYES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1980-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324085-A1 | AZABICYCLIC CARBAMATES AND THEIR USE AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | CHRNA7, CHRNA5, CHRNA4 | KLKB1 3618/4885CTSB 2254/4885PTGS1 3386/4885 |
| US-20150065537-A1 | AZABICYCLIC CARBAMATES AND THEIR USE AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | CHRNA7, CHRNA5, CHRNA4 | KLKB1 3618/4885CTSB 2254/4885PTGS1 3386/4885 |
| US-20180127409-A1 | AZABICYCLIC CARBAMATES AND THEIR USE AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | CHRNA7, CHRNA5, CHRNA4 | KLKB1 3618/4885CTSB 2254/4885PTGS1 3386/4885 |
| US-20130060039-A1 | AZABICYCLIC CARBAMATES AND THEIR USE AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | CHRNA7, CHRNA5, CHRNA4 | KLKB1 3618/4885CTSB 2254/4885PTGS1 3386/4885 |
| US-20120046350-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | PPARG, PPARD, PPARA | KLKB1 2903/4885CTSB 1852/4885PTGS1 354/4885 |
| US-10196388-B2 | Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists | CHRNA7, CHRNA5, CHRNA4 | KLKB1 3618/4885CTSB 2254/4885PTGS1 3386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.